Article | June 20, 2022

The No. 1 Most Common Problem In FDA GMP Inspections

By Sarah Beale, MasterControl

Inspection scientist GettyImages-1180581833

COVID-19 had a dramatic impact on the inspectional activities of the U.S. Food and Drug Administration (FDA). The number of good manufacturing practices (GMP) inspections that could be completed understandably decreased and the agency found itself relying more on remote methods. While FDA oversight now looks quite different than before the pandemic, the biggest problem in FDA GMP inspections hasn't changed.

When it comes to pharmaceutical manufacturing, year after year, the same problem is at the top of the list for both FDA warning letters and Form 483s — issues involving quality responsibilities and procedures. We uncover how embracing digitization and adopting an eQMS to manage quality processes can make this problem a thing of the past.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online